Hyperopia

Summary

Hyperopia (MONDO:0004891) is a disease caused by MYRF (GenCC Strong), with 10 cohort genes (4 GWAS associations across 7 studies) and 122 clinical trials. Top therapeutic interventions include codeine, levofloxacin anhydrous, and nepafenac.

At a glance

• Causal gene: MYRF (GenCC Strong)
• Cohort genes: 10
• GWAS associations: 4
• ClinVar variants: 12
• Clinical trials: 122

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hyperopia
Mondo ID	MONDO:0004891
MeSH	D006956
DOID	DOID:9834
ICD-10-CM	H52.0
SNOMED CT	38101003
UMLS	C0020490
MedGen	43780
Is cancer (heuristic)	no

Also known as: hypermetropia

Data availability: 12 ClinVar variants · 4 GWAS associations (7 studies) · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › refractive error › hyperopia

Related subtypes (6): aniseikonia, presbyopia, myopia, transient refractive change, anisometropia, astigmatism

Genetics & variants

GWAS landscape

4 GWAS associations across 7 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs429358	1e-07	APOE	C	1.77
rs2352179	2e-07	GRID1	T	1.67
rs78011035	3e-06	PARP8 - LINC02106	A	2.47
rs10153386	8e-06	GTSCR1 - LINC01541	G	2.01

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90079387	Backman JD	2021	23,800	3,778	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083373	Backman JD	2021	23,800	3,778	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90079385	Backman JD	2021	2,102	25,476	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083371	Backman JD	2021	2,102	25,476	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90079386	Backman JD	2021	1,912	25,666	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083372	Backman JD	2021	1,912	25,666	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST008740	Shaaban S	2018	361	1,700	Genome-Wide Association Study Identifies a Susceptibility Locus for Comitant Esotropia and Suggests a Parent-of-Origin Effect.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	2
missense_variant	1
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs429358	19	44908684	T>C	0.05	missense_variant	APOE	1e-07	Tier 1: coding
rs2352179	10	86030323	C>A,T	0.05	intron_variant	GRID1	2e-07	Tier 4: intronic/intergenic
rs78011035	5	50881621	G>A,T	0.05	intergenic_variant	PARP8 - LINC02106	3e-06	Tier 4: intronic/intergenic
rs10153386	18	70948356	A>G	0.05	intergenic_variant	GTSCR1 - LINC01541	8e-06	Tier 4: intronic/intergenic

ClinVar germline variants

12 retrieved; paginated sample, class counts are floors:

5 pathogenic, 4 uncertain significance, 3 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
268035	46;XX;t(19;21)(q13.3;q22.3)dn		Pathogenic	criteria provided, single submitter
242882	NM_013275.6(ANKRD11):c.5317G>T (p.Glu1773Ter)	ANKRD11	Pathogenic	no assertion criteria provided
1173069	NM_005916.5(MCM7):c.776G>C (p.Gly259Ala)	MCM7	Pathogenic	criteria provided, multiple submitters, no conflicts
1804007	NM_005916.5(MCM7):c.133C>T (p.Gln45Ter)	MCM7	Pathogenic	criteria provided, single submitter
1804042	NM_144643.4(SCLT1):c.1043del (p.Ser348fs)	SCLT1	Pathogenic	criteria provided, single submitter
183286	NM_172225.2(DMBX1):c.352C>T (p.Arg118Trp)	DMBX1	Likely pathogenic	no assertion criteria provided
2430245	NM_002235.5(KCNA6):c.1367T>A (p.Val456Asp)	KCNA6	Likely pathogenic	criteria provided, single submitter
1804041	NM_144643.4(SCLT1):c.2060dup (p.Asn687fs)	SCLT1	Likely pathogenic	criteria provided, single submitter
523302	GRCh37/hg19 5p14.3-14.2(chr5:22308420-24492723)	CDH10	Uncertain significance	criteria provided, single submitter
523282	GRCh37/hg19 6p24.1-23(chr6:12536624-13968949)	RNF182	Uncertain significance	criteria provided, single submitter
523398	NM_001379110.1(SLC9A6):c.1190C>A (p.Ala397Glu)	SLC9A6	Uncertain significance	criteria provided, single submitter
523487	NM_005802.5(TOPORS):c.2666A>G (p.His889Arg)	TOPORS	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MYRF	Strong	Autosomal dominant	hyperopia	7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MYRF	Orphanet:647811	Cardiac-urogenital syndrome
SLC9A6	Orphanet:85278	Christianson syndrome
ANKRD11	Orphanet:2332	KBG syndrome
ANKRD11	Orphanet:261250	16q24.3 microdeletion syndrome
TOPORS	Orphanet:2754	Orofaciodigital syndrome type 6
TOPORS	Orphanet:791	Retinitis pigmentosa
SCLT1	Orphanet:110	Bardet-Biedl syndrome
MCM7	Orphanet:2512	Autosomal recessive primary microcephaly

Cohort genes → proteins

10 cohort genes, 10 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	10

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MYRF	HGNC:1181	ENSG00000124920	Q9Y2G1	Myelin regulatory factor	gencc
SLC9A6	HGNC:11079	ENSG00000198689	Q92581	Sodium/hydrogen exchanger 6	clinvar
CDH10	HGNC:1749	ENSG00000040731	Q9Y6N8	Cadherin-10	clinvar
DMBX1	HGNC:19026	ENSG00000197587	Q8NFW5	Diencephalon/mesencephalon homeobox protein 1	clinvar
ANKRD11	HGNC:21316	ENSG00000167522	Q6UB99	Ankyrin repeat domain-containing protein 11	clinvar
TOPORS	HGNC:21653	ENSG00000197579	Q9NS56	E3 ubiquitin-protein ligase Topors	clinvar
SCLT1	HGNC:26406	ENSG00000151466	Q96NL6	Sodium channel and clathrin linker 1	clinvar
RNF182	HGNC:28522	ENSG00000180537	Q8N6D2	E3 ubiquitin-protein ligase RNF182	clinvar
KCNA6	HGNC:6225	ENSG00000151079	P17658	Potassium voltage-gated channel subfamily A member 6	clinvar
MCM7	HGNC:6950	ENSG00000166508	P33993	DNA replication licensing factor MCM7	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MYRF	Myelin regulatory factor	Constitutes a precursor of the transcription factor.
SLC9A6	Sodium/hydrogen exchanger 6	Endosomal Na(+), K(+)/H(+) antiporter.
CDH10	Cadherin-10	Cadherins are calcium-dependent cell adhesion proteins.
DMBX1	Diencephalon/mesencephalon homeobox protein 1	Functions as a transcriptional repressor.
ANKRD11	Ankyrin repeat domain-containing protein 11	Chromatin regulator which modulates histone acetylation and gene expression in neural precursor cells.
TOPORS	E3 ubiquitin-protein ligase Topors	Functions as an E3 ubiquitin-protein ligase and as an E3 SUMO1-protein ligase.
SCLT1	Sodium channel and clathrin linker 1	Adapter protein that links SCN10A to clathrin.
RNF182	E3 ubiquitin-protein ligase RNF182	E3 ubiquitin-protein ligase that mediates the ubiquitination of ATP6V0C and targets it to degradation via the ubiquitin-proteasome pathway.
KCNA6	Potassium voltage-gated channel subfamily A member 6	Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes.
MCM7	DNA replication licensing factor MCM7	Acts as a component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for ‘once per cell cycle’ DNA replication initiation and elongation in eukaryotic cells.

Protein-family classification

Druggable: 1 · Difficult: 5 · Unknown: 4 · Druggable fraction: 0.1

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	4	3.3×	0.099
Ion channel	1	11.2×	0.172
Scaffold/PPI	1	1.7×	0.599
Other/Unknown	4	0.7×	0.907

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MYRF	Transcription factor	no		p53-like_TF_DNA-bd_sf, NDT80_DNA-bd_dom, MYRF_C2
SLC9A6	Other/Unknown	no		NHE-6/7/9, NaH_exchanger, Cation/H_exchanger_TM
CDH10	Other/Unknown	no		Cadherin_Y-type_LIR, Cadherin-like_dom, Cadherin-like_sf
DMBX1	Transcription factor	no		HD, OAR_dom, Homeodomain-like_sf
ANKRD11	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf, ANKRD11
TOPORS	Transcription factor	no		Znf_RING, Znf_RING/FYVE/PHD, Znf_RING_CS
SCLT1	Other/Unknown	no		SCLT1
RNF182	Transcription factor	no		Znf_RING, Znf_RING/FYVE/PHD, Znf_RING_CS
KCNA6	Ion channel	yes		BTB/POZ_dom, T1-type_BTB, K_chnl_volt-dep_Kv
MCM7	Other/Unknown	no		MCM_dom, AAA+_ATPase, MCM7

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	10
unknown	0

Top tissues across cohort

Tissue	Cohort genes
middle temporal gyrus	2
male germ line stem cell (sensu Vertebrata) in testis	2
cortical plate	2
ganglionic eminence	2
C1 segment of cervical spinal cord	1
inferior vagus X ganglion	1
middle frontal gyrus	1
lateral nuclear group of thalamus	1
pons	1
Brodmann (1909) area 23	1
Brodmann (1909) area 46	1
primordial germ cell in gonad	1
upper arm skin	1
stromal cell of endometrium	1
sural nerve	1
tendon of biceps brachii	1
calcaneal tendon	1
secondary oocyte	1
sperm	1
buccal mucosa cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MYRF	223	ubiquitous	marker	middle frontal gyrus, C1 segment of cervical spinal cord, inferior vagus X ganglion
SLC9A6	286	ubiquitous	yes	lateral nuclear group of thalamus, middle temporal gyrus, pons
CDH10	172	broad	marker	Brodmann (1909) area 23, middle temporal gyrus, Brodmann (1909) area 46
DMBX1	33	broad	yes	male germ line stem cell (sensu Vertebrata) in testis, upper arm skin, primordial germ cell in gonad
ANKRD11	278	ubiquitous	marker	tendon of biceps brachii, sural nerve, stromal cell of endometrium
TOPORS	285	ubiquitous	marker	secondary oocyte, calcaneal tendon, sperm
SCLT1	217	ubiquitous	marker	buccal mucosa cell, monocyte, leukocyte
RNF182	192	broad	yes	endothelial cell, cortical plate, ganglionic eminence
KCNA6	123	tissue_specific	yes	cortical plate, male germ line stem cell (sensu Vertebrata) in testis, prefrontal cortex
MCM7	143	ubiquitous	marker	embryo, ganglionic eminence, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MCM7	5,413
ANKRD11	2,384
SLC9A6	1,867
TOPORS	1,552
SCLT1	1,478
KCNA6	1,399
CDH10	1,322
MYRF	979
DMBX1	678
RNF182	508

Structural data

PDB: 2 · AlphaFold-only: 8 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MCM7	P33993	28
MYRF	Q9Y2G1	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
SCLT1	Q96NL6	82.44
CDH10	Q9Y6N8	78.29
KCNA6	P17658	75.42
RNF182	Q8N6D2	70.67
SLC9A6	Q92581	70.61
DMBX1	Q8NFW5	63.71
TOPORS	Q9NS56	49.39
ANKRD11	Q6UB99	39.44

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 42. Enrichment computed across 10 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective SLC9A6 causes X-linked, syndromic mental retardation,, Christianson type (MRXSCH)	1	1631.4×	0.026	SLC9A6
Sodium/Proton exchangers	1	181.3×	0.067	SLC9A6
DNA strand elongation	1	163.1×	0.067	MCM7
SUMOylation of immune response proteins	1	135.9×	0.067	TOPORS
Unwinding of DNA	1	125.5×	0.067	MCM7
SUMOylation of SUMOylation proteins	1	46.6×	0.073	TOPORS
Activation of the pre-replicative complex	1	46.6×	0.073	MCM7
DNA Replication Pre-Initiation	1	45.3×	0.073	MCM7
Activation of ATR in response to replication stress	1	42.9×	0.073	MCM7
Switching of origins to a post-replicative state	1	42.9×	0.073	MCM7
Synthesis of DNA	1	42.9×	0.073	MCM7
Adherens junctions interactions	1	35.5×	0.073	CDH10
Cell-cell junction organization	1	35.5×	0.073	CDH10
Voltage gated Potassium channels	1	34.7×	0.073	KCNA6
SUMOylation of transcription cofactors	1	34.7×	0.073	TOPORS
DNA Replication	1	34.0×	0.073	MCM7
G1/S Transition	1	33.3×	0.073	MCM7
SLC transporter disorders	1	29.1×	0.074	SLC9A6
Cell junction organization	1	26.7×	0.074	CDH10
Mitotic G1 phase and G1/S transition	1	26.3×	0.074	MCM7
S Phase	1	25.9×	0.074	MCM7
Orc1 removal from chromatin	1	25.5×	0.074	MCM7
Disorders of transmembrane transporters	1	19.9×	0.079	SLC9A6
Assembly of the pre-replicative complex	1	19.9×	0.079	MCM7
Cell-Cell communication	1	19.7×	0.079	CDH10
Potassium Channels	1	19.2×	0.079	KCNA6
G2/M Checkpoints	1	19.2×	0.079	MCM7
R-HSA-425393	1	18.5×	0.079	SLC9A6
Anchoring of the basal body to the plasma membrane	1	16.1×	0.087	SCLT1
Cilium Assembly	1	15.5×	0.088	SCLT1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 10 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
central nervous system myelin maintenance	1	280.9×	0.045	MYRF
regulation of phosphorylation	1	280.9×	0.045	MCM7
clustering of voltage-gated sodium channels	1	240.7×	0.045	SCLT1
DNA strand elongation involved in DNA replication	1	187.2×	0.045	MCM7
adult feeding behavior	1	168.5×	0.045	DMBX1
dendrite extension	1	168.5×	0.045	SLC9A6
double-strand break repair via break-induced replication	1	129.6×	0.045	MCM7
maintenance of protein location in nucleus	1	112.3×	0.045	TOPORS
regulation of DNA-templated DNA replication initiation	1	105.3×	0.045	MCM7
photoreceptor cell outer segment organization	1	105.3×	0.045	TOPORS
central nervous system myelination	1	99.1×	0.045	MYRF
positive regulation of myelination	1	76.6×	0.045	MYRF
response to immobilization stress	1	73.3×	0.045	MYRF
developmental growth	1	73.3×	0.045	DMBX1
positive regulation of oligodendrocyte differentiation	1	67.4×	0.045	MYRF
retina layer formation	1	64.8×	0.045	TOPORS
protein autoprocessing	1	64.8×	0.045	MYRF
DNA replication initiation	1	62.4×	0.045	MCM7
sodium ion import across plasma membrane	1	62.4×	0.045	SLC9A6
oligodendrocyte development	1	60.2×	0.045	MYRF
regulation of intracellular pH	1	60.2×	0.045	SLC9A6
response to cocaine	1	58.1×	0.045	MYRF
synaptic membrane adhesion	1	58.1×	0.045	CDH10
adherens junction organization	1	51.1×	0.045	CDH10
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	49.6×	0.045	TOPORS
axon extension	1	49.6×	0.045	SLC9A6
skeletal system morphogenesis	1	49.6×	0.045	ANKRD11
face morphogenesis	1	49.6×	0.045	ANKRD11
calcium-dependent cell-cell adhesion	1	48.1×	0.045	CDH10
potassium ion transmembrane transport	2	27.2×	0.045	SLC9A6, KCNA6

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 10

Druggability breadth: 2 of 10 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MYRF	0	0
SLC9A6	0	0
CDH10	0	0
DMBX1	0	0
ANKRD11	0	0
TOPORS	0	0
SCLT1	0	0
RNF182	0	0
KCNA6	0	0
MCM7	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KCNA6	29	Binding:24, Functional:3, Toxicity:1, ADMET:1
MCM7	9	Binding:9

Pharmacogenomics

Cohort genes with a PharmGKB record: 10; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	1	KCNA6
E	Difficult family or no structure, no drug	9	MYRF, SLC9A6, CDH10, DMBX1, ANKRD11, TOPORS, SCLT1, RNF182, MCM7

Undrugged target profiles

10 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MYRF	0	—
SLC9A6	0	—
CDH10	0	—
DMBX1	0	—
ANKRD11	0	—
TOPORS	0	—
SCLT1	0	—
RNF182	0	—
KCNA6	29	—
MCM7	9	—

Clinical trials & evidence

Clinical trials

Clinical trials: 122.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	98
PHASE4	10
PHASE3	6
PHASE1/PHASE2	5
PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00347204	PHASE4	COMPLETED	Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00455455	PHASE4	COMPLETED	Corneal and Conjunctival Sensitivity and Staining Study
NCT00937105	PHASE4	COMPLETED	Daily Wear Corneal Infiltrative Event Study
NCT01387360	PHASE4	COMPLETED	Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
NCT01977807	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK
NCT02071576	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK
NCT02112968	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia
NCT03881670	PHASE4	COMPLETED	On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
NCT04208750	PHASE4	COMPLETED	Clinical Investigation of the Vision-R800 Device.
NCT04283331	PHASE4	UNKNOWN	Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)
NCT00520689	PHASE3	COMPLETED	Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens
NCT00910403	PHASE3	COMPLETED	Multicenter Evaluation of Safety and Effectiveness of Presbyopic LASIK for Hyperopes
NCT00928122	PHASE3	UNKNOWN	Intrastromal Correction of Ametropia by a Femtosecond Laser
NCT01028378	PHASE3	COMPLETED	Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia
NCT01322919	PHASE3	COMPLETED	Safety and Efficacy Study to Evaluate the Treatment of Both Near and Distance Vision in a Simultaneous Laser Procedure
NCT05247658	PHASE3	TERMINATED	Use of a Disk of Amniotic Membrane (Visio-AMTRIX) in Postoperative Care After PKR
NCT00574717	PHASE1/PHASE2	TERMINATED	Enhancement of Emmetropization in Hyperopic Infants
NCT01024855	PHASE1/PHASE2	COMPLETED	Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
NCT01893359	PHASE1/PHASE2	TERMINATED	Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism
NCT02148016	PHASE1/PHASE2	UNKNOWN	Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation
NCT04883996	PHASE1/PHASE2	UNKNOWN	A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia
NCT05477875	PHASE2	COMPLETED	Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control
NCT01556893	PHASE1	COMPLETED	Creating LASIK Flaps With the LenSx Femtosecond Laser
NCT06742541	EARLY_PHASE1	COMPLETED	ICL and LASIK for Hyperopic Astigmatism
NCT04616144	Not specified	ACTIVE_NOT_RECRUITING	Fresh Corneal Lenticule Implantation in Hyperopic Patients With High Astigmatism
NCT04632784	Not specified	ACTIVE_NOT_RECRUITING	Clinical Trial With Artiflex Presbyopic (Artiplus)
NCT04692012	Not specified	ACTIVE_NOT_RECRUITING	Treatment of Residual Hypermetropic Refraction on Pseudophakic Patients Using Allogenic Fresh Myopic Lenticule
NCT04712318	Not specified	ENROLLING_BY_INVITATION	Treatment of Residual Refraction Errors 6 Months After Trifocal IOL Implantation With Relex-Smile
NCT05264623	Not specified	ACTIVE_NOT_RECRUITING	Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
NCT05689567	Not specified	ACTIVE_NOT_RECRUITING	Focus-out Glasses on Emmetropization in Chinese Children
NCT06484257	Not specified	ACTIVE_NOT_RECRUITING	Comparison Between Myopia Versus Hypermetropia With Progressive Addition Lenses in Computer Users
NCT06597292	Not specified	NOT_YET_RECRUITING	The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.
NCT07133737	Not specified	ENROLLING_BY_INVITATION	5 Year Follow up of SMILE® Procedure for the Correction of Hyperopia
NCT07135570	Not specified	RECRUITING	My Eyes, My Light: Amar Chokh, Amar Alo
NCT07142915	Not specified	NOT_YET_RECRUITING	Effect of Light-Blocking Lenses on Pediatric Hyperopia
NCT07142928	Not specified	NOT_YET_RECRUITING	Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children
NCT07240480	Not specified	NOT_YET_RECRUITING	Assessing the Turkish DDIVAT for Visual Acuity Measurement
NCT07401511	Not specified	NOT_YET_RECRUITING	Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia
NCT00348205	Not specified	COMPLETED	A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
NCT00363623	Not specified	COMPLETED	Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CODEINE	4	1
LEVOFLOXACIN ANHYDROUS	4	1
NEPAFENAC	4	1
PROPARACAINE	4	1
LOTRAFILCON B	3	3
ENFILCON A	3	1
ETAFILCON A	3	1
OCUFILCON D	3	1
SENOFILCON A	3	1